Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ (marstacimab-hncq) for routine ...
Pfizer’s Mylotarg is back ... after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody-drug conjugate, where a targeted antibody ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...
Pfizer has won European Commission approval of its Hympavzi treatment for certain patients with the blood-clotting disorder hemophilia. The New York drugmaker on Wednesday said the approval covers ...
Nov 22 (Reuters) - (This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) The oral drug, branded as Attruby, was approved to ...
Based on these results, the FDA approved this drug for a similar indication last month ... The latest decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in ...